Tandem Diabetes Care (TNDM) Shares Up 23.4%

Tandem Diabetes Care Inc (NASDAQ:TNDM) shot up 23.4% during mid-day trading on Tuesday . The company traded as high as $3.13 and last traded at $3.11. 1,351,300 shares traded hands during mid-day trading, an increase of 232% from the average session volume of 407,060 shares. The stock had previously closed at $2.52.

A number of brokerages have recently issued reports on TNDM. Zacks Investment Research raised shares of Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $2.75 target price for the company in a research report on Wednesday, December 6th. Robert W. Baird reaffirmed a “hold” rating and issued a $3.00 price target on shares of Tandem Diabetes Care in a research note on Sunday, November 19th. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $15.00 price target on shares of Tandem Diabetes Care in a research note on Friday, October 6th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $17.00 price target (down previously from $50.00) on shares of Tandem Diabetes Care in a research note on Tuesday, October 10th. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company has an average rating of “Hold” and an average target price of $11.29.

The stock has a market capitalization of $34.71, a P/E ratio of -0.17 and a beta of 0.17. The company has a current ratio of 1.90, a quick ratio of 0.88 and a debt-to-equity ratio of -2.70.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its quarterly earnings results on Thursday, October 26th. The medical device company reported ($3.09) EPS for the quarter, beating the Zacks’ consensus estimate of ($3.74) by $0.65. The company had revenue of $27.00 million during the quarter, compared to analyst estimates of $25.92 million. The firm’s revenue for the quarter was up 119.7% compared to the same quarter last year. During the same period last year, the firm earned ($0.97) EPS. equities research analysts anticipate that Tandem Diabetes Care Inc will post -15.37 EPS for the current year.

In related news, CEO Kim D. Blickenstaff purchased 285,700 shares of the company’s stock in a transaction that occurred on Friday, October 13th. The stock was acquired at an average price of $3.50 per share, with a total value of $999,950.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 20.90% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. raised its stake in Tandem Diabetes Care by 2.7% during the second quarter. Vanguard Group Inc. now owns 1,233,607 shares of the medical device company’s stock worth $987,000 after acquiring an additional 32,991 shares in the last quarter. Keybank National Association OH raised its stake in Tandem Diabetes Care by 32.7% during the second quarter. Keybank National Association OH now owns 293,206 shares of the medical device company’s stock worth $235,000 after acquiring an additional 72,177 shares in the last quarter. Russell Investments Group Ltd. raised its stake in Tandem Diabetes Care by 13.5% during the third quarter. Russell Investments Group Ltd. now owns 659,993 shares of the medical device company’s stock worth $482,000 after acquiring an additional 78,748 shares in the last quarter. Finally, Wedbush Securities Inc. raised its stake in Tandem Diabetes Care by 88.6% during the third quarter. Wedbush Securities Inc. now owns 188,877 shares of the medical device company’s stock worth $138,000 after acquiring an additional 88,709 shares in the last quarter.

WARNING: This report was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://www.com-unik.info/2018/01/11/tandem-diabetes-care-tndm-shares-up-23-4.html.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).

What are top analysts saying about Tandem Diabetes Care? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Tandem Diabetes Care and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit